Retatrutide

Known as a "triple agonist," Retatrutide acts on three key metabolic receptors — GLP-1, GIP, and glucagon — to simultaneously suppress appetite, improve insulin sensitivity, and boost the body's energy expenditure and fat-burning. Clinical trials show unprecedented weight loss, approaching the results of bariatric surgery.

How It Works

Retatrutide goes a step further than current medications like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) by targeting an additional pathway:

• GLP-1: Reduces appetite, slows digestion, and promotes fullness.
• GIP: Improves insulin secretion and helps the body manage nutrients.
• Glucagon: Stimulates fat breakdown and increases the body's energy expenditure (calorie burning).

Clinical Trial Results

In clinical studies, Retatrutide has demonstrated remarkable efficacy for both weight management and metabolic health:

• Weight Loss: Phase 2 and Phase 3 trials showed participants lost an average of 24% to nearly 30% of their starting body weight over the course of the studies.
• Type 2 Diabetes: Retatrutide significantly lowered HbA1c levels, with many participants achieving numbers associated with diabetes remission.
• Additional Benefits: Trials are also investigating its effectiveness against conditions like fatty liver disease (MASH), obstructive sleep apnea, and knee osteoarthritis.